Advances in #cancer treatment have improved clinical outcomes, leading to an increasing population of cancer survivors. Yet, this success is associated with high rates of short‐ & long‐term #cardiovascular toxicities. The Cancer Patient and Cardiology onlinelibrary.wiley.com/doi/abs/10.100…
The number & variety of #cancer drugs & #cardiovascular toxicity types make long‐term care a complex undertaking.
This requires a multidisciplinary approach including expertise from #oncology, #cardiology, & other related specialties, & has led to the development of the cardio‐oncology subspecialty.
This article provides an overview of the main adverse events, risk assessment & mitigation strategies, early diagnosis, medical & complementary strategies for prevention & management, & follow‐up strategies for patients at risk of #cancer therapy‐related cardiotoxicities.
Research is needed to better define strategies for early identification, follow‐up, & management.
While the academic cardio‐oncology community may be the best vehicle to foster awareness & research in this field, additional stakeholders (industry, government & patient organisations) should be involved to facilitate interactions & help the design & funding of trials.
The overarching goal of cardio‐oncology is to assist clinicians in providing optimal care for patients with cancer & for #cancer survivors, to provide insight into future areas of research & to search for collaborations with industry, funding bodies, & patient advocates.
However, many unmet needs remain.
This article is the product of brainstorming presentations & active discussions held at the Cardiovascular Round Table workshop organised in January 2020 by the European Society of Cardiology @escardio
The Cancer Patient and Cardiology @ESC_Journals onlinelibrary.wiley.com/doi/abs/10.100…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.